Management of patients with advanced ovarian cancer - Role of complete cytoreduction and HIPEC: Attitudes of gynaecologist oncologists in two different continents
Spiliotis, J.; Iavazzo, C.; Sugarbaker, P.
Australian and New Zealand Journal of Obstetrics and Gynaecology 61(1): E1-E2
2021
ISSN/ISBN: 1479-828X PMID: 33523489 DOI: 10.1111/ajo.13229Document Number: 372153
Document emailed within 0-6 h
Related Documents
Robella, M.; Vaira, M.; Marsanic, P.; Mellano, A.; Borsano, A.; Cinquegrana, A.; Sottile, A.; De Simone, M. 2014: Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) Minerva Chirurgica 69(1): 27-35Gasowska-Bodnar, A.; Bodnar, L.; Wcisło, G.B.; Jerzak, M.łg.M.; Szczylik, C.; Baranowski, W.ło. 2008: CA 125 regression after two cycles of neoadjuvant chemotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction Ginekologia Polska 79(2): 108-114
Donato, M.L.; Champlin, R.E.; Wharton, J.T.; Bodurka-Bevers, D.; Gershenson, D. 2000: Intensive-dose ifosfamide and etoposide with filgrastim for cytoreduction before peripheral blood stem cell collection in patients with advanced ovarian cancer European Journal of Gynaecological Oncology 21(3): 241-244
Zanaboni, F.; Heintz, A.P.; Trimbos, J.B.; van Lindert, A.C.; Aalders, J.G.; Neijt, J.P. 1988: The role of cytoreduction in ovarian cancer European Journal of Gynaecological Oncology 9(2): 149-152
Wolfberg, A.J.; Montz, F.J.; Bristow, R.E. 2004: Role of obesity in the surgical management of advanced-stage ovarian cancer Journal of Reproductive Medicine 49(6): 473-476
Neijt, J.P. 1995: Interval cytoreduction in ovarian cancer New England Journal of Medicine 333(4): 254-255; Author Reply 255
Cherchi, P.L.; Dessole, S.; Esposito, F.; Ambrosini, G.; El Qandil, F.Z.; Ambrosini, A. 1996: Interperitoneal alpha-2b interferon for advanced ovarian cancer in complete remission or minimal residual disease Journal de Gynecologie Obstetrique et Biologie de la Reproduction 25(1): 101-102
Mataga, V.; Matković, V. 2013: Role of neoadjuvant chemotherapy in the advanced ovarian cancer Lijecnicki Vjesnik 135(1-2): 21-26
Sun, X.; Li, X.; Li, H. 1995: Management of intestinal obstruction in advanced ovarian cancer an analysis of 57 cases Zhonghua Zhong Liu Za Zhi 17(1): 39-42
Wu, M.; Lang, J.; Huang, R. 1996: Management and prognosis of advanced ovarian cancer associated with bowel metastasis and obstruction Zhonghua Fu Chan Ke Za Zhi 31(10): 617-620
Romanidis, K.; Nagorni, E.-A.; Halkia, E.; Pitiakoudis, M. 2014: The role of cytoreductive surgery in advanced ovarian cancer: the general surgeon's perspective Journal of Buon: Official Journal of the Balkan Union of Oncology 19(3): 598-604
Rose, P.G.; Hunter, R.E. 1994: Advanced ovarian cancer in a woman with a family history of ovarian cancer, discovered at referral for prophylactic oophorectomy. A case report Journal of Reproductive Medicine 39(11): 908-910
Markowska, J.; Madry, R.ła.; Kierzkowski, J.; Malicki, J.; Roszak, A.; Lubin, J.; Bratos, K. 2003: Radioimmunotherapy in patients with ovarian cancer in complete remission after the first line surgery and chemotherapy after second look laparoscopy procedure Ginekologia Polska 74(9): 799-804
González-Del-Alba Baamonde, A.án.; Sevillano Fernández, E. 2018: The role of corticoids in the management of advanced prostate cancer Archivos Espanoles de Urologia 71(3): 281-287
Markman, M.; Francis, P.; Rowinsky, E.; Hoskins, W. 1995: Intraperitoneal paclitaxel: a possible role in the management of ovarian cancer? Seminars in Oncology 22(3 Suppl 6: 84-87
Schwartz, P.E. 2008: What is the role of neoadjuvant chemotherapy in the management of ovarian cancer? Oncology 22(10): 1118-1125; Discussion 1130 1132, 1134
Bertucci, F.; Viens, P.; Gravis, G.; Blaise, D.; Faucher, C.; Oziel-Taoeb, S.; Bardou, V.J.; Jacquemier, J.; Delpero, J.R.; Maraninchi, D. 1999: High-dose chemotherapy with hematopoietic stem cell support in patients with advanced epithelial ovarian cancer: analysis of 67 patients treated in a single institution Anticancer Research 19(2b): 1455-1461
Krommer, K. 1992: Treatment of patients with advanced ovarian cancer at the Gynecological Clinic of Pécs Medical University Orvosi Hetilap 133(19): 1151-1158
Du Bois, A.; Lück, H.J.; Meier, W.; Möbus, V.; Costa, S.; Richter, B.; Warm, M.; Bauknecht, T.; Schröder, W.; Olbricht, S.; Nitz, U.; Jackisch, C. 1997: Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase IIi trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group Seminars in Oncology 24(5 Suppl 15: S15
Gadducci, A.; Cianci, C.; Cosio, S.; Carnino, F.; Fanucchi, A.; Buttitta, F.; Conte, P.F.; Genazzani, A.R. 2000: P53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen Anticancer Research 20(6c): 4793-4799